LBT Innovations Limited (AU:LBT) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Australian medical technology firm LBT Innovations has secured a lucrative deal with AstraZeneca, involving the sale of five APAS® Independence instruments and a seven-year maintenance contract, potentially reaching AU$4.1 million. This agreement, following positive validation studies, highlights the growing commercial interest from large pharmaceutical companies in LBT’s AI-driven microbiology automation technology. The initial installations are slated for the upcoming six months, with expectations of further orders.
For further insights into AU:LBT stock, check out TipRanks’ Stock Analysis page.